Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights
Portfolio Pulse from Benzinga Insights
Over the past three months, 12 analysts have shared their insights on Apellis Pharmaceuticals (NASDAQ:APLS), with opinions ranging from bullish to bearish. The average 12-month price target is $76.17, down 6.77% from the previous average of $81.70. Recent analyst actions include several downgrades and maintained ratings, reflecting mixed sentiments.
July 17, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have mixed views on Apellis Pharmaceuticals, with a 12-month price target averaging $76.17, down 6.77% from the previous average. Recent ratings include several downgrades and maintained positions, reflecting varied sentiments.
The mixed analyst ratings and the decrease in the average price target suggest uncertainty about Apellis Pharmaceuticals' short-term performance. While some analysts maintain a bullish outlook, others have downgraded their ratings, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100